Point: Sentinel Lymph Node Biopsy Is Indicated for Patients With DCIS

View More View Less
  • 1 Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York

Sentinel lymph node (SLN) biopsy, a new standard of care for staging invasive breast cancer, remains controversial for ductal carcinoma in situ (DCIS). Although DCIS has a natural history in which long-term distant disease-free survival (DDFS) is 98% to 99% and axillary node metastases are historically rare, three recent DCIS series have found SLN metastases in a surprising 6% to 13% of patients. The strongest argument for SLN biopsy in DCIS is the diagnostic uncertainty and inherent sampling error of conventional pathologic techniques. Definitive surgery (excision or mastectomy) reveals invasive cancer in 10% to 21% of patients with a preoperative core needle or surgical biopsy diagnosis of DCIS, all of whom become conventional candidates for SLN biopsy. In the absence of proven invasion, most positive SLN in DCIS are micrometastases detected by hematoxylin and eosin– and immunohistochemical-stained serial sections. An increasing body of evidence suggests that these are prognostically significant, not artifactual. We propose that DCIS patients with positive SLN have occult invasive cancers, and that the same may have been true for the 1% to 2% of DCIS patients who go on to develop distant metastasis, either after an invasive local recurrence or as a first event. We further suggest that the diagnosis of DCIS encompasses two patient populations: 1) a majority (perhaps 90%) with true in situ disease (or prognostically insignificant invasion), negative SLNs, and an expected DDFS of 100%; and 2) a minority (perhaps 10%) with occult invasion, positive SLNs, and an expected DDFS of perhaps 90%. Pending the development of predictive models for preoperative identification of this SLN-positive minority of DCIS patients, SLN biopsy is indicated in any DCIS patient who may have an underlying invasive cancer, especially those who require mastectomy. In DCIS, SLN biopsy may ultimately prove to be a more sensitive screening test for occult invasion than examination of the breast itself.

Correspondence: Hiram S. Cody III, MD, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021. E-mail: codyh@mskcc.org
  • 1

    Krag DN, Weaver DL, Alex JC et al. . Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993;2:335340.

    • Search Google Scholar
    • Export Citation
  • 2

    Giuliano AE, Kirgan DM, Guenther JM et al. . Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;220:391401.

  • 3

    Cody HS. Clinical aspects of sentinel node biopsy. Breast Cancer Res 2001;3:104108.

  • 4

    Giuliano AE, Dale PS, Turner RR et al. . Improved staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995;3:394401.

  • 5

    Temple LK, Baron R, Cody HS III et al. . Sensory morbidity after sentinel lymph node biopsy and axillary dissection: A prospective study of 233 women. Ann Surg Oncol 2002;9:654662.

    • Search Google Scholar
    • Export Citation
  • 6

    Bedrosian I, Reynolds C, Mick R et al. . Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. Cancer 2000;88:25402545.

    • Search Google Scholar
    • Export Citation
  • 7

    Olson JA, Fey J, Winawer J et al. . Sentinel lymphadenectomy accurately predicts nodal status in T2 breast cancer. J Am Coll Surg 2000;191:593599.

  • 8

    Breslin TM, Cohen L, Sahin A et al. . Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2000;18:34803486.

    • Search Google Scholar
    • Export Citation
  • 9

    Dupont EL, McCann C, Shons AR et al. . The role of sentinel lymph node biopsy in women undergoing prophylactic mastectomy. Am J Surg 2000;180:274277.

    • Search Google Scholar
    • Export Citation
  • 10

    Silverstein MJ, Gierson ED, Colburn WJ et al. . Axillary lymphadenectomy for intraductal carcinoma of the breast. Surg Gynecol Obstetrics 1991;172:211214.

    • Search Google Scholar
    • Export Citation
  • 11

    Ernster VL, Barclay J, Kerlikowske K et al. . Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med 2000;160:953958.

    • Search Google Scholar
    • Export Citation
  • 12

    van Dongen JA, Fentiman IS, Harris JR et al. . In-situ breast cancer: The EORTC consensus meeting. Lancet 1989;2:2527.

  • 13

    van Dongen JA, Holland R, Peterse JL et al. . Ductal carcinoma in-situ of the breast; second EORTC consensus meeting. Eur J Cancer 1992;28:626629.

  • 14

    Recht A, van Dongen JA, Fentiman IS et al. . Third meeting of the DCIS Working Party of the EORTC (Fondazione Cini, Isola S. Giorgio, Venezia, 28 February 1994)—Conference report. Eur J Cancer 1994;30A:18951900.

    • Search Google Scholar
    • Export Citation
  • 15

    Recht A, Rutgers EJ, Fentiman IS et al. . The fourth EORTC DCIS Consensus meeting (Chateau Marquette, Heemskerk, The Netherlands, 23–24 January 1998)—Conference report. Eur J Cancer 1998;34:16641669.

    • Search Google Scholar
    • Export Citation
  • 16

    The Consensus Conference Committee. The consensus conference on the classification of ductal carcinoma in situ. Cancer 1997;80:17981802.

    • Search Google Scholar
    • Export Citation
  • 17

    Schwartz GF, Solin LJ, Olivotto IA et al. . The consensus conference on the treatment of in situ ductal carcinoma of the breast, April 22-25, 1999. Breast J 2000;6:413.

    • Search Google Scholar
    • Export Citation
  • 18

    Fisher B, Dignam J, Wolmark N et al. . Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from the National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998;16:441452.

    • Search Google Scholar
    • Export Citation
  • 19

    Fisher B, Dignam J, Wolmark N et al. . Tamoxifen in the treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999;353:19932000.

    • Search Google Scholar
    • Export Citation
  • 20

    Julien J-P, Bijker N, Fentiman IS et al. . Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: First results of the EORTC randomised phase III trial 10853. Lancet 2000;355:528533.

    • Search Google Scholar
    • Export Citation
  • 21

    Kestin LL, Goldstein NS, Martinez AA et al. . Mammographically detected ductal carcinoma in situ treated with conservative surgery with or without radiation therapy: Patterns of failure and 10-year results. Ann Surg 2000;231:235245.

    • Search Google Scholar
    • Export Citation
  • 22

    Silverstein MJ. The Van Nuys/University of Southern California experience by treatment. In Silverstein MJ (ed). Ductal Carcinoma In Situ of the Breast. Philadelphia: Lippincott Williams & Wilkins, 2002:337342.

    • Search Google Scholar
    • Export Citation
  • 23

    Silverstein MJ (ed). Ductal Carcinoma In Situ of the Breast. Philadelphia: Lippincott Williams & Wilkins, 2002.

  • 24

    NCCN. The Complete Library of Practice Guidelines in Oncology: Breast Cancer (version 1). 2002: www.nccn.org.

  • 25

    Lagios MD, Silverstein MJ. Sentinel node biopsy for patients with DCIS: A dangerous and unwarranted direction. Ann Surg Oncol 2001;8:275277.

    • Search Google Scholar
    • Export Citation
  • 26

    Pendas S, Dauway E, Giuliano AE et al. . Sentinel node biopsy in duct carcinoma in situ patients. Ann Surg Oncol 2000;7:1520.

  • 27

    Cox CE, Nguyen K, Gray RJ et al. . Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): Why map DCIS? Am Surg 2001;67:513519.

  • 28

    Klauber-DeMore N, Tan LK, Liberman L et al. . Sentinel lymph node biopsy: Is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion? Ann Surg Oncol 2000;7:636642.

    • Search Google Scholar
    • Export Citation
  • 29

    Cody HS III, Klauber-DeMore N, Borgen PI et al. . Is it really duct carcinoma in situ? Ann Surg Oncol 2001;8:617619.

  • 30

    Chieng DC, Fernandez G, Cangiarella JF et al. . Invasive carcinoma in clinically suspicious breast masses diagnosed as adenocarcinoma by fine-needle aspiration. Cancer 2000; 90:96101.

    • Search Google Scholar
    • Export Citation
  • 31

    Fisher ER, Costantino J, Fisher B et al. . Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Intraductal carcinoma (ductal carcinoma in situ). The National Surgical Adjuvant Breast and Bowel Project Collaborating Investigators. Cancer 1995;75:13101319.

    • Search Google Scholar
    • Export Citation
  • 32

    Bijker N, Peterse JL, Duchateau L et al. . Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: Analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 2001;19:22632271.

    • Search Google Scholar
    • Export Citation
  • 33

    Liberman L. Percutaneous image-guided core breast biopsy. Radiol Clin North Am 2002;40:483500.

  • 34

    Liberman L. Centennial dissertation. Percutaneous imaging-guided core breast biopsy: State of the art at the millennium. AJR Am J Roentgenol 2000;174:11911199.

    • Search Google Scholar
    • Export Citation
  • 35

    Darling ML, Smith DN, Lester SC et al. . Atypical ductal hyperplasia and ductal carcinoma in situ as revealed by large-core needle breast biopsy: Results of surgical excision. AJR Am J Roentgenol 2000;175:13411346.

    • Search Google Scholar
    • Export Citation
  • 36

    Jackman RJ, Burbank F, Parker SH et al. . Stereotactic breast biopsy of nonpalpable lesions: Determinants of ductal carcinoma in situ underestimation rates. Radiology 2001;218: 497502.

    • Search Google Scholar
    • Export Citation
  • 37

    Liberman L, Benton CL, Dershaw DD et al. . Learning curve for stereotactic breast biopsy: How many cases are enough? AJR Am J Roentgenol 2001;176:721727.

    • Search Google Scholar
    • Export Citation
  • 38

    Morrow M, Venta L, Stinson T et al. . Prospective comparison of stereotactic core biopsy and surgical excision as diagnostic procedures for breast cancer patients. Ann Surg 2001;233:537541.

    • Search Google Scholar
    • Export Citation
  • 39

    Fourquet A, de la Rochfordiere A, Campana F. Occult primary breast cancer with axillary metastases. In Harris JR, Lippman ME, Morrow M, Hellman S (eds). Diseases of the Breast. Philadelphia: Lippincott-Raven, 1996:892896.

    • Search Google Scholar
    • Export Citation
  • 40

    Swallow CJ, Van Zee KJ, Sacchini V et al. . Ductal carcinoma in situ of the breast: progress and controversy. Curr Probl Surg 1996;33:556600.

  • 41

    Silverstein MJ, Lagios MD, Martino S et al. . Outcome after invasive local recurrence in patients with ductal carcinoma in situ of the breast. J Clin Oncol 1998;16:13671373.

    • Search Google Scholar
    • Export Citation
  • 42

    Solin LJ, Fourquet A, Vicini FA et al. . Mammographically detected ductal carcinoma in situ of the breast treated with breast-conserving surgery and definitive breast irradiation: Long-term outcome and prognostic significance of patient age and margin status. Int J Radiat Oncol Biol Phys 2001;50:9911002.

    • Search Google Scholar
    • Export Citation
  • 43

    Huvos AG, Hutter RV, Berg JW. Significance of axillary macrometastases and micrometastases in mammary cancer. Ann Surg 1971;173:4446.

  • 44

    Dowlatshahi K, Fan M, Snider HC et al. . Lymph node micrometastases from breast carcinoma: Reviewing the dilemma. Cancer 1997;80:11881197.

  • 45

    International (Ludwig) Breast Cancer Study Group. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet 1990;335:15651568.

    • Search Google Scholar
    • Export Citation
  • 46

    Cote RJ, Peterson HF, Chaiwun B et al. . Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group [see comments]. Lancet 1999;354:896900.

    • Search Google Scholar
    • Export Citation
  • 47

    Tan LK, Giri D, Panageas K et al. . Occult micrometastases in axillary lymph nodes of breast cancer patients are significant: A retrospective study with long-term follow-up (Abstr). Proc ASCO 2002;21:37a, #146.

    • Search Google Scholar
    • Export Citation
  • 48

    Giuliano AE, Haigh PI, Brennan M et al. . Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol 2000;18:25532559.

    • Search Google Scholar
    • Export Citation
  • 49

    Krag DN, Harlow S, Weaver D et al. . Radiolabeled sentinel node biopsy: Collaborative trial with the national cancer institute. World J Surg 2001;25:823828.

    • Search Google Scholar
    • Export Citation
  • 50

    Liberman L. Pathologic analysis of sentinel lymph nodes in breast carcinoma. Cancer 2000;88:971977.

  • 51

    Weiser MR, Montgomery LL, Tan LK et al. . Lymphovascular invasion enhances the prediction of non-sentinel node metastases in breast cancer patients with positive sentinel nodes. Ann Surg Oncol 2001;8:145149.

    • Search Google Scholar
    • Export Citation
  • 52

    Moore KM, Tan LK, Cody HS et al. . What is the clinical significance of a positive sentinel node in a patient with DCIS? Soc Surg Oncol 2003, in press.

  • 53

    Rosser RJ. A point of view: Trauma is the cause of occult micrometastatic breast cancer in sentinel axillary lymph nodes. Breast J 2000;6:209212.

    • Search Google Scholar
    • Export Citation
  • 54

    Carter BA, Jensen RA, Simpson JF et al. . Benign transport of breast epithelium into axillary lymph nodes after biopsy. Am J Clin Pathol 2000;113:259265.

    • Search Google Scholar
    • Export Citation
  • 55

    Liberman L, Cody HS, Hill ADK et al. . Sentinel lymph node biopsy after percutaneous diagnosis of nonpalpable breast cancer. Radiology 1999;211:835844.

    • Search Google Scholar
    • Export Citation
  • 56

    American Joint Committee on Cancer. AJCC Cancer Staging Manual (Fifth Edition). Philadelphia: Lippincott-Raven, 1997.

  • 57

    American Joint Committee on Cancer. AJCC Cancer Staging Manual (Sixth Edition). New York: Springer-Verlag, 2002.

  • 58

    Ravdin PM, Siminoff IA, Harvey JA. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol 1998;16:515521.

    • Search Google Scholar
    • Export Citation
  • 59

    Simes RJ, Coates AS. Patient preferences for adjuvant chemotherapy of early breast cancer: How much benefit is needed? J Natl Cancer Inst Monogr 2001;146152.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 1 0 0
Full Text Views 829 280 18
PDF Downloads 707 285 12
EPUB Downloads 0 0 0